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1. Introduction 
With more than 1 million annual deaths, among both females and males, lung cancer is the 
world leading cause of cancer-related death (1). The most important risk factor for lung 
cancer is smoking, with smokers presenting a 10 fold risk increase compared to non-
smokers. Lung cancers are usually divided into two categories: small-cell lung cancer 
(SCLC), representing approximately 15% of cases, and non-small cell lung cancer (NSCLC). 
This sub-division represents around 85% of all lung cancer cases and includes the 
histological sub-types adenocarcinoma, large-cell carcinoma and squamous cell carcinoma 
(2). The lung cancer 5-year survival rate is one of the lowest at 10-15% and treatment 
depends on the extent of the disease at the time of diagnosis (3). Approximately 30% of 
patients have early stage lung cancer when diagnosed and those tumours can be surgically 
removed, 20% have local and/or regionally advanced tumours and are treated with chemo 
and radiotherapy, and almost half of the patients have advanced metastatic disease when 
only palliative treatments are available (4). Consequently there is a pressing need for new 
screening and early diagnostic techniques that are specific and non-invasive, and also for 
tools that can predict prognosis, optimize treatments and identify new therapeutic targets. 
Genomic approaches have been used to that end in the last years. Nonetheless, given the 
importance of proteins to a cells’ phenotype, post-translational modifications, and the poor 
correlation between mRNA and protein expression levels (5, 6), proteomic analyses may 
enlighten the pathogenesis of lung cancer. A variety of techniques such as two dimensional 
gel electrophoresis (2D-PAGE, 2D-DIGE), protein arrays, protein labelling and tagging 
(ICAT, iTRAQ, SILAC), are being used in cancer research (7, 8) and have the potential to aid 
clinical practice as a complement to histopathology, as a selection method for individualized 
therapy, and in the assessment of drug efficacy, resistance, and toxicity (9). 
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2. Lung cancer 
In the beginning of the 20th century, lung cancer was a rare disease. Nowadays it has the 
highest incidence and mortality rates in the world with lifestyle and environmental factors 
thought to be the major contributors to the development of this disease (10).  
Epidemiological evidence has shown that two to three decades after a peak in smoking 
prevalence in a given population, there is a peak in lung cancer deaths, making tobacco 
smoking the main cause of lung cancer development. This relationship was established in 
the 1950’s and 60’s (10-12). Other causes include environmental tobacco smoking, air 
pollution, indoor radon, occupational exposure to respiratory carcinogens, asbestos, and 
fumes from cooking stoves and fires (10). Even though smoking is undeniably the major 
cause of lung cancer, making it the leading cause of preventable death in the world, it is 
important to recognize that the majority of smokers will not develop this neoplasia over 
time and that this is probably due to individual variation in the susceptibility to respiratory 
carcinogens and the existence of a previous lung disease (13, 14). Tobacco components can 
induce DNA damage through several mechanisms including gene point mutations, 
deletions, insertions, recombinations, rearrangements, and chromosomal alterations, which 
drive the development of the disease (15). Nonetheless, the current classification of lung 
cancer does not emphasize the important of specific molecular and genetic alterations that 
can differentiate between SCLC and NSCLC. This is also true for the NSCLC subtypes 
adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, that were until 
recently, treated similarly, regardless of their biological heterogeneity (16). Lung cancer is 
characterized by genetic instability of the chromosomes, nucleotides, and the transcriptome. 
These abnormalities are usually targeted to proto-oncogenes, tumour suppressor genes, 
DNA repair genes, among others. The silencing of telomerase is present in normal cells, but 
in almost all SCLC and over 80% of NSCLC, telomerase is activated, promoting cell 
immortalization (17). The epidermal growth factor receptor (EGFR) is overexpressed or 
abnormally activated by mutation in 50-90% of all NSCLC, especially in squamous cell 
carcinomas, leading to increased cell proliferation and survival through the 
RAS/RAF/MEK/MAPK and PI3K/AKT pathways (18). Activating mutations of the KRAS 
gene from the RAS proto-oncogene family are present in 20% of all NSCLS and between 30-
50% of lung adenocarcinomas (19). The fusion of the echinoderm microtubule-associated 
protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) genes occurs in 
approximately 7% of NSCLC and is associated with a persistent mitogenic signal. The 
EML4-ALK, EGFR, and KRAS mutations are almost always mutually exclusive (19). Tumour 
suppressor genes are also affected in lung cancer. Mutations in TP53 are the most common 
genetic alterations found in human cancers and occur in approximately 75% of SCLC and in 
50% of NSCLC (17). Alterations in the PI3K/AKT pathway, the CDKN2A/RB1 pathway, 
VEGF, and epigenetic changes are also present in lung cancer (19). Several drugs have been 
developed to target these alterations and improve survival of lung cancer patients, such as 
tyrosine kinase inhibitors and monoclonal antibodies, revealing the importance of the 
molecular characterization of tumours in order to improve detection, diagnosis, treatment 
and prognosis of lung cancer. 
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Proteins are crucial operators in the majority of biological systems and a comprehensive 
knowledge of their expression, modifications, and function in the lung cancer setting, may 
be more informative than DNA and RNA studies alone. New technologies are being 
developed that allow the analysis of thousands of cancer cell proteins, possibly generating 
new therapeutic targets and biomarkers that will have an impact on early detection, therapy 
and prognostic evaluation of lung cancer patients. 
3. Proteomic techniques in lung cancer research 
The proteomic technologies which are being implemented in lung cancer research are 
mainly based on two dimensional gel electrophoresis, as seen on Figure 1 where the 2D-
PAGE and 2D-DIGE workflows are represented, or proteomics based on isotope labelling 
methods as ICAT, iTRAQ, SILAC, followed by mass spectrometry (MS) analysis.  
 
Figure 1. Basic workflow of gel-based proteomic approaches. In 2D-PAGE, protein samples are 
separated according to their isoelectric point in a process termed isoelectric focusing, using gel strips 
with a fixed pH range. Then, the focused strip is placed on top of a polyacrylamide gel to allow proteins 
to separate according to their molecular weight during electrophoresis, generating a gel with protein 
spots. In 2D-DIGE, proteins from up to three samples are labelled with fluorescent dyes prior to their 
isoelectric focusing and subsequent gel electrophoresis. Gels are scanned with different wavelengths 
revealing spots and differences in expression between analysed samples. Protein spots of interest in 
both techniques are then excised, digested, and identified by MS. 
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4. Two dimensional gel electrophoresis 2D-PAGE 
2D-PAGE is the most used proteomic technique for studying the proteome as well as to 
search for cancer biomarkers (20, 21). In this methodology intact proteins are firstly 
separated by their isoelectric point (pI) and then according to their molecular weight. This 
procedure generates protein spots that are separated from the gel and digested into peptides 
for MS identification. Multidimensional separation of peptides may also be required given 
that, although the digestion step facilitates the identification process, it increases sample 
complexity, decreasing the sensitivity and coverage of the technique. Disadvantages of 2D-
PAGE include the separation of low abundant proteins and of membrane proteins. The use 
of fractioning methods or higher protein concentrations for less detectable proteins and the 
use of mild detergents to increase the solubility of membrane proteins may be a solution for 
the aforementioned issues (22, 23). Other problems include co-migration of different 
proteins, the separation of a protein with different post-translational modifications, proteins 
with pI values below 4 or above 9, or the separation of very small or very large proteins. 
Differential gel electrophoresis (2D-DIGE), a modification of 2D-PAGE with fluorescent 
dyes (Cy3, Cy5 and Cy2), is able to increase reproducibility and throughput and also allows 
the accurate quantitation of protein expression difference (24). Differential analysis software 
can recognize the differentially expressed proteins and these can later be trypsin digested 
into peptides generating peptide mass fingerprints (PMF). The absolute masses of these 
peptides can be measured by matrix assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS), a technique that is both relatively easy to use and 
reasonably sensitive for identifying proteins. Additionally other MS techniques, such as 
electrospray ionization (ESI-MS/MS), are capable of providing amino acid sequence 
information on peptide fragments of the initial protein (25). Liquid chromatography coupled 
to tandem mass spectrometry workflow (LC-MS/MS) has become a standard method to 
identify proteins from complex biological samples. Also, direct MS analysis of tissue, known 
as MALDI imaging, is a method that has been used to elucidate proteome features 
characterizing histological differences in lung cancer between adenocarcinoma and 
squamous- cell carcinoma (26). Another example of a novel way to generate proteomic data 
is presented in the study of dynamic proteome changes on lung cancer cells (H1299) treated 
with the cytotoxic drug camptothecin using single-protein labelling on large scale (27). 
5. Isotope-labelled mass spectrometry 
Isotope-labelling methods, as seen on Figure 2, are gel-free procedures that introduce stable 
isotope tags to proteins through chemical reactions using isotope-coded affinity tags (ICAT) 
(28) and isobaric tag for relative and absolute quantitation (iTRAQ) (29), or through 
metabolic labelling with isotope labelled amino acids in cell culture (SILAC) (30). 
ICAT is used to analyse pairs of protein samples, such as a treated sample and its control. 
Extracted proteins from both samples are labelled with a light or heavy ICAT reagent by 
reacting with a specific amino acid (cysteine). Samples are then mixed, trypsin digested, 
fractioned, and analysed by LC-MS/MS (31). Isotope peak ratios for each peptide determine 
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the differential protein expression. The drawback of this technique is that it can only analyse 
cysteine containing proteins, two samples, and it can only identify 300-400 peptides. 
 
Figure 2. Basic workflow of gel-free quantitative approaches in proteomics. In SILAC, one cellular 
culture is grown in normal medium and the other with a growth medium with heavy labelled amino-
acids. In ICAT, one protein extract is labelled with a light ICAT reagent and the other with a heavy 
ICAT reagent. In both techniques, samples are mixed, digested, separated and analysed by MS to 
determine protein identity and differential expression. In iTRAQ, special isobaric tags are applied in 4 
to 8 samples up for comparison. They are then pooled together, fractionated and analysed by MS, 
allowing protein identification and quantitation among studied samples. 
iTRAQ is another labelling technique first developed by Ross and co-workers (32) which 
uses isobaric tags to label and compare proteins extracted from samples. iTRAQ contains a 
set of four or eight isobaric reagents and therefore can analyse up to four or eight protein 
samples at one time. After trypsin digestion samples are labelled with four or eight (4-plex 
or 8-plex) independent iTRAQ reagents. The reporter groups of the iTRAQ reagents 
separate from the peptides and generate small fragments for each sample with mass-to-
charge (m/z) of 114, 115, 116, and 117 for 4-plex, plus 113, 118, 119, and 121 for 8-plex. The 
intensity of each peak correlates with the quantity of each reporter group and thus with the 
quantity of the peptide. This method allows the analysis of various samples at a time and 
also, given that most peptides are suitable to be labelled by iTRAQ, it minimizes 
information loss and allows the identification of proteins with different post-translational 
modifications. Disadvantages of iTRAQ include a separate lengthy sample processing, that 
increases the chances of experimental errors, and the generation of chemical side products 
during the labelling process that can reduce the sensitivity of the method (33). 
SILAC, first developed by Mann and co-workers, is based on the metabolic incorporation of 
“heavy” and “light” forms of amino acids into the proteins of living cultured cells (34) . 
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Typically, heavy (13C or 15N) arginine or lysine are used in the culture medium of a cell 
culture while the other cell culture is supplied with regular amino acids. After several 
division rounds, these amino acids are incorporated into the newly synthesized proteins. 
Following trypsin digestion, peptides are analysed by MS and the light and heavy peptides 
appear in two distinct peaks and, by comparing the signal intensities differences, relative 
quantitation can be performed. This technique has been widely used for cancer biomarker 
discovery (35), and cell signalling dynamics (36).  
6. Label-free mass spectrometry 
Multidimensional Protein Identification Technology (MudPIT) is a generic label-free LC-MS 
shotgun screening method (36). It separates peptides according to two independent 
physicochemical properties using liquid chromatography (LC/LC) online with the ion 
source of a mass spectrometer, allowing the separation and identification of peptides 
without labelling. The success of this technique depends on the experimental workflow, 
from protein extraction to sample stability, given that the reproducibility of technical 
replicates is better than that of experimental replicates. Drawbacks of this method include 
the fact that not all peptides are equally detectable given the competition between ions, 
dynamic range limitations and MS sensitivity (37). With time and improvements, label-free 
MS could be widely used for biomarker discovery and validation. 
7. Detection of post-translational modifications (PTMs) 
PTMs are the chemical alterations that occur to a protein after translation. They include 
proteolytic cleavage, glycosylation, phosphorylation, acetylation, ubiquitination, 
farnesylation, methylation, sialylation, oxidation, prolyl isomerization and hydroxylation 
(38). Glycosylation and phosphorylation are two of the most biologically relevant PTMs and 
appear to be key processes in tumour progression in many types of cancers including lung 
cancer (39, 40) 
Glycosylation, the process of adding saccharides to proteins, plays a fundamental role in 
protein stabilization, molecular and cellular recognition, growth and cellular 
communication, and can also be a part of immune responses and cancer progression (41). 
The comparative study of the carbohydrate chains of glycoproteins may provide useful 
information for the diagnosis, prognosis, and immunotherapy of tumours (42). The 
proteomic analysis of glycoproteins starts with the enrichment of these molecules from a 
complex protein sample by the use lectins. This step is followed by a separation of 
glycoproteins by procedures such as 2D-PAGE and 2D-DIGE coupled with glycoprotein 
staining methods, for example Pro-Q Emerald 488 glycoprotein stain (43), lectin fluorescence 
stain (44), and isotope labelling (45). Identification of separated glycoproteins and their 
glycan structures can be accomplished by chromatographic methods (nano-LC with 
hydrophilic columns, nano-LC with graphitized carbon packing, anion-exchange 
chromatography), electromigration approaches (capillary electrophoresis, capillary 
electrochromatography), capillary LC/MALDI-TOF/TOF MS & tandem MS (MS/MS), and 
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chip-based approaches (46). Although there are some difficulties when analysing lung 
tumours, one study has identified 34 glycoproteins with significant differences between 
lung adenocarcinomas and healthy controls. The α1,6-fucosylation levels were incremented 
in the lung cancer group in comparison with healthy group (47). 
Phosphorylation is the addition of a phosphate group to a protein and is a key regulatory 
mechanism of cellular signalling processes. Phosphoproteomics and the characterization of 
phosphorylation sites, which less than 2% are currently known, are some of the most 
challenging tasks in current proteomic research (48). To isolate and identify phosphorylated 
proteins one must use immunoaffinity or immunoprecipitation with a specific antibody, 
chromatofocusing, ion exchange chromatography and affinity chromatography, such as 
immobilized metal ion affinity chromatography (IMAC) (49). Separation methods include 
electrophoresis, 2D-PAGE or 2D-DIGE coupled with phosphoprotein staining (Pro-Q 
Diamond phosphoprotein gel stain) or isotope labelling (ICAT, SILAC) (50, 51). Analysis 
and identification methods of phosphoproteins and phosphopeptides are mass 
spectrometry-based approaches, such MALDI-TOF MS, LC-ESI-MS and MS/MS (52). Given 
that the key regulators of signalling cascades are kinases and phosphatases, lung cancer 
phosphoproteomics might reveal the correlation between phosphorylation and cancer 
mechanisms.  
8. Samples in lung cancer proteomics 
The lung is a heterogeneous organ composed by several highly differentiated cells 
(bronchial, alveolar, inflammatory) and vascular structures. Its main function is to 
perform gas exchanges between the atmosphere and the bloodstream. When studying 
lung cancer with proteomic tools, several different samples can be used: tumour tissue, 
blood, pleural effusions, among others (53). The accessibility of blood makes for a great 
sample for oncoproteomic studies. Moreover, it contains many circulating molecules 
secreted by the tumour that can be used as biomarkers. Nonetheless, due to the 
abundance of plasma proteins, depletion of these proteins is necessary to reveal the 
presence of less abundant ones. Tumour tissue samples, fresh-frozen or formalin-fixed 
and paraffin-embedded, are the ideal for any oncoproteomic study. However, adjacent 
normal tissue, inflammatory cells, stromal components, and others might also be present. 
This will result in non-tumour derived protein contamination. To compensate tumour 
heterogeneity careful sample cell content analysis and the increase of sample numbers is 
required to obtain relevant results. The pleura is a thin double-layered tissue that 
surrounds the lung and it is filled with pleural fluid. This liquid is constantly produced 
and reabsorbed, and its main function is to facilitate respiratory movements and reduce 
attrition between the lungs and the thorax wall. Pleural effusion is the pathological 
accumulation of fluid that occurs in inflammatory conditions and lung cancer. In the latter 
case, pleural effusion is often drained to search for cancer cell infiltration. Its protein 
composition is similar to plasma, but its proximity to tumour cells makes it useful for lung 
cancer biomarker detection by proteomic techniques. 
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9. Proteomics in the discovery and validation of lung cancer biomarkers 
9.1. Diagnostic biomarkers 
To discover a lung cancer diagnostic biomarker, a molecule that is specific and directly 
correlates with the presence of this disease, the majority of studies perform a comparison 
between the protein profiles of tumour samples and normal lung tissue. The ideal would be 
to study the development of the carcinogenic process from normal tissue, to metaplasia, to 
dysplasia, and finally to invasive cancer, in order to discover early markers of disease before 
the onset of clinical features. 
In response to inflammation, a cancer enabling characteristic, acute-phase reactant proteins 
(APRPs) are produced. Recent proteomic studies have shown that APRPs haptoglobin (Hp) 
β chain (54), serum amyloid A (SAA) (55), and apolipoprotein A-1 (Apo A-1) (56) proteins 
are potential lung cancer diagnostic biomarkers. SAA proteins are involved in the transport 
of cholesterol to the liver, the recruitment of immune cells, and the induction extracellular 
matrix degrading enzymes. SAA1 and SAA2, which are synthesised in response to activated 
monocytes/macrophages, were recently identified, by LC-MS/MS, ELISA and 
immunohistochemistry analyses, as lung cancer biomarkers given their higher expression 
levels in blood and tissue from lung cancer patients when compared to healthy subjects and 
patients with other cancers and respiratory diseases (55). In another related study, serum 
and pleural effusions from NSCLC patients were compared by 2D-DIGE to those from 
patients with benign lung diseases. Gelsolin, possibly involved in cancer invasion, 
metalloproteinase inhibitor 2 (TIMP2), involved in lung parenchyma disorganization, and 
pigment epithelium derived factor (PEDF), an angiogenesis inhibitor, were among the 
candidate biomarkers (57). A study by Patz and co-workers, that aimed to test the diagnostic 
performance of four lung cancer biomarkers (carcinoembryonic antigen and squamous-cell 
carcinoma antigen, and 2D-PAGE and MALDI-MS discovered retinol binding protein – RBP 
- and α-1 antitrypsin), demonstrated that the four markers have inadequate diagnostic 
power when tested independently but proved useful when used in combination (58). A 
glycoproteomic study revealed plasma kallikrein (KLKB1), pleural effusion periostin, 
multimerin-2, CD166 and lysosome-associated membrane glycoprotein-2 (LAMP-2) as 
potential lung cancer biomarkers (59).  
9.2. Prognostic biomarkers 
Prognostic biomarkers, those that have expression levels correlating with the natural history 
of the disease, have the potential to influence survival by identifying high-risk patients and 
thus improve their management. The study of prognostic biomarkers in lung cancer has 
been made by correlating the expression of a molecule to the patient survival. An alternative 
approach is to compare groups of patients with different clinical stages of disease, based on 
the assumption that a more advanced tumour is more aggressive and may express proteins 
that drive the metastatic process. Proteomic studies have aimed at discovering altered 
protein levels and subsequently validating those differences using immunohistochemistry 
on archive samples. Using 2D-PAGE, Chen and co-workers associated 11 components of the 
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glycolysis pathway to poor survival in lung adenocarcinoma (39) and also demonstrated 
their prognostic role in lung cancer at the mRNA level. Nonetheless, glycolysis involved 
enzyme phosphoglycerate kinase 1 was found to limit tumour growth in mice 
subcutaneously injected with the Lewis lung carcinoma cell line, by promoting antitumor 
immunity (60). A study using 2D-DIGE, MS, western blot, and immunohistochemistry 
correlated the up-regulation of annexin A3, a protein associated with cancer metastasis by 
angiogenic promotion, with advanced clinical stage, lymph node metastasis, increased 
relapse time, and overall decreased survival in lung adenocarcinoma, indicating that 
annexin A3 might be a prognostic lung cancer biomarker (61). The involvement of S100A11, 
a small calcium-binding protein implicated in the prognosis and metastasis in several 
tumours, has also been evaluated in lung cancer. Comparative proteomic analysis of two 
NSCLC cell lines, the non-metastatic CL1-0 and highly metastatic CL1-5, revealed that 
S100A11 was up-regulated in metastatic CL1-5 cells (62). Moreover, immunohistochemical 
analyses in NSCLC tissues showed that the up-regulation of S100A11 was significantly 
associated with a higher TNM stage and a positive lymph node status, indicating its 
importance in promoting invasion and metastasis of NSCLC. Altered expression of S100A6 
was also implicated in NSCLC progression: elevated levels of this protein were associated 
with longer survival compared to S100A6-negative cases (63). Cytoskeletal reorganization is 
a central process regulating cell migration and metastasis and cytokeratins (CKs), a family of 
cytoskeletal intermediate filaments, have been suggested to play a role in carcinogenesis, by 
promoting cellular architecture reorganization during tumour development and 
progression. A 2D-PAGE and MS analysis has revealed that isoforms of CK7, 8, 18, and 19 
were found in higher levels in adenocarcinoma samples than in adjacent tissues (64). 
Specific isoforms of the CKs were associated with unfavourable prognosis, CYFRA21-1 was 
a more accurate diagnostic marker, and CK18 was a stronger prognostic factor (65). Other 
cytoskeletal proteins found to be correlated with a poor prognosis in lung adenocarcinoma 
are non-muscle myosin IIA and vimentin proteins, involved in epithelial-mesenchymal 
transition, a process at the basis of invasive and metastatic behaviour (66). Phosphohistidine 
phosphatase (PHP14) was proposed to be another lung cancer prognostic biomarker, 
regulating cell migration and invasion by cytoskeleton rearrangement. Indeed, it has been 
shown that PHP14 knockdown in highly metastatic lung cancer cells (CL1-5) inhibited 
migration and invasion, whereas its over-expression in NCI H1299 cells enhanced these 
processes (67). Calmodulin, a protein implicated in cytoskeletal alterations during cell death, 
thymosin β4, a regulator of actin polymerization whose over-expression seems to stimulate 
lung tumour metastasis, thymosin β10 and cofilin proteins, regulators of actin dynamics,  
were identified and their expression and prognostic role validated on cohort of 188 lung 
cancer cases (68). 
9.3. Predictive biomarkers  
The discovery of predictive biomarkers, those on which the efficacy of a specific treatment 
can be foreseen, has been based on studying clinical samples from responding and non-
responding patients and then validating results on selected cohorts. This type of biomarker 
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aims at individualizing therapies in lung cancer but relies on extremely well characterized 
samples from cohorts of patients receiving a uniform treatment and closely monitored 
therapeutic responses. A recent MALDI-TOF-MS study that profiled serum from patients 
treated with cisplatin-gemcitabine in combination with the proteasome inhibitor 
bortezomib,  revealed a 13-peptide signature that was able to distinguish with high 
accuracy, sensitivity, and specificity, patients with short and long progression-free survival 
(69). The epidermal growth factor receptor (EGFR) tyrosine kinase is an important target for 
treatment of NSCLC, and EGFR-inhibitor-based therapies have showed promising results. 
The serum MALDI-MS study conducted by Taguchi and co-workers in NSCLC patients  
 
Type of Biomarker Proteins Techniques 
Diagnostic 
Hp β chain (54) LC-ESI-MS/MS, ELISA 
SAA1
SAA2 (55)
LC-MS/MS, ELISA, IHC 
Apo A1 (56) 2D-PAGE, MALDI-TOF 
Gelsolin
TIMP2 
PEDF (57) 
2D-DIGE 
RBP
α-1 antitrypsin (58) 2D-DIGE, MALDI-TOF-MS 
KLKB1
Periostin 
Multimerin-2 
CD166 
LAMP-2 (59) 
LC-MS/MS 
Prognostic 
Glycolysis
(11 components) (39)
2D-PAGE 
Annexin A3 (61) 2D-DIGE, MS, IHC* 
S100A11 (62) 2D-PAGE, MALDI-TOF-MS/MS, IHC 
S100A6 (63) SELDI-TOF-MS 
CK 7, 8, 9 and 19 (64) 2D-PAGE, MS 
CYFRA21-1
CK18 (65)
ELISA 
Myosin IIA
Vimentin (66) 
LC-MS/MS 
PHP14 (67) 2D-PAGE, ESI-TOF-MS/MS 
Calmodulin
Thymosin β4 
Thymosin β10 (68)
MALDI-MS, IHC 
Predictive 
13-peptide signature (69) MALDI-TOF-MS 
8-peak signature (70) MALDI-MS 
* Immunohistochemistry 
Table 1. Potential lung cancer biomarkers discovered by the use of proteomic tools 
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treated with gefitinib and erlotinib revealed an 8-peak profile predictive of outcome (70). 
This 8-peak signature was commercially launched as a commercial product (Veristrat ®, 
Biodesix, Broom field, CO, US) and its clinical relevance is being validated in the context of a 
randomized phase III clinical trial where patients with advanced NSCLC progressing after 
first-line treatment, stratified according to serum MALDI-MS profiling, are subsequently 
randomly allocated to receive either erlotinib or chemotherapy as second-line therapy 
(PROSE, Proteomics Stratified Erlotinib trial). To the best of our knowledge, this is the only 
clinical trial investigating the predictive role of a proteomics biomarker in lung cancer 
patients. A summary of all mentioned biomarkers can be found on Table 1. 
10. Conclusions 
Proteomic approaches are improving rapidly and the development of high-throughput 
platforms is showing promising results as the list of candidate biomarkers for lung cancer is 
continuously growing. However, there is a great need for careful interpretation of this 
intricate data in order to generate biologically relevant hypotheses. The proteome is highly 
complex and current tools cannot yet provide a definitive solution for its exploration. In 
addition, cancer is a multifactorial disease so diverse that a great deal of time and effort will 
be necessary to define its associated proteome modifications and to translate these into 
practical clinical applications. In fact for many of the identified proteins, their functional role 
in lung cancer development is not yet known and a solid clinical validation is still lacking. 
Nonetheless, it is likely that some of these candidate biomarkers will serve to identify new 
possible therapeutic strategies. 
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